As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.
We have now initiated a collaboration with Prof. Pradhan who is a world leader in delta opioid neurobiology with a particular interest in migraine and with Prof. Eamonn Kelly (University of Bristol) our existing research partner and opioid expert with the intention of applying for NIH funding to synthesize and test a range of new DORA structures. The aim is to develop new compounds for treating migraine and other headaches.
Success could lead to new patents following up on our lead compound PN6047 and entry into the large international migraine/headache market.
22 MSEK new funding
PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.Read more →
As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.Read more →
New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.Read more →
JPET approves PN6047
In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).Read more →